Literature DB >> 24724819

Predictors of hippocampal atrophy in critically ill patients.

A Lindlau1, C N Widmann, C Putensen, F Jessen, A Semmler, M T Heneka.   

Abstract

BACKGROUND AND
PURPOSE: Hippocampal atrophy is presumably one morphological sign of critical illness encephalopathy; however, predictors have not yet been determined.
METHODS: The data for this report derived from patients treated at the intensive care units (ICUs) of the University Hospital in Bonn in the years 2004-2006. These patients underwent structural magnetic resonance imaging 6-24 months after discharge. Volumes (intracranial, whole brain, white matter, grey matter, cerebral spinal fluid, bilateral hippocampus) were compared with healthy controls. Pro-inflammatory parameters and ICU scoring systems were explored in conjunction with brain volumes. Cut-scores were defined to differentiate patients with high from those with low inflammatory response.
RESULTS: Hippocampal and white matter volume were reduced in critically ill patients compared with healthy controls. Procalcitonin showed a very strong correlation (r = -0.903, P = 0.01) and interleukin-6 a moderate correlation (r = -0.538, P = 0.031) with hippocampal volume, but not with other brain volumes. C-reactive protein was linked to grey matter volume. There was no correlation with systemic inflammatory response syndrome criteria (body temperature, heart rate, respiratory rate, white blood cell count) or for hippocampal or whole brain volume. Furthermore, parameters representing severity of disease (APACHE II score, SOFA score, duration of stay and duration of mechanical ventilation) were not associated with hippocampal or other brain volumes.
CONCLUSIONS: This analysis suggests that high levels of procalcitonin and interleukin-6 in the blood serum of critically ill patients are associated with a high likelihood of hippocampal atrophy irrespective of the severity of disease measured by ICU scoring systems and other inflammatory parameters.
© 2014 The Author(s) European Journal of Neurology © 2014 EAN.

Entities:  

Keywords:  critical illness; hippocampus; inflammation; neurodegenerative disorders; structural MRI

Mesh:

Year:  2014        PMID: 24724819     DOI: 10.1111/ene.12443

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  9 in total

1.  Who Will Develop Epilepsy Following Hospital Discharge? Think Again.

Authors:  Adriana Bermeo-Ovalle
Journal:  Epilepsy Curr       Date:  2018 May-Jun       Impact factor: 7.500

2.  Long-term microstructure and cerebral blood flow changes in patients recovered from COVID-19 without neurological manifestations.

Authors:  Yuanyuan Qin; Jinfeng Wu; Tao Chen; Jia Li; Guiling Zhang; Di Wu; Yiran Zhou; Ning Zheng; Aoling Cai; Qin Ning; Anne Manyande; Fuqiang Xu; Jie Wang; Wenzhen Zhu
Journal:  J Clin Invest       Date:  2021-04-15       Impact factor: 14.808

3.  Altered inflammatory activity associated with reduced hippocampal volume and more severe posttraumatic stress symptoms in Gulf War veterans.

Authors:  Aoife O'Donovan; Linda L Chao; Jennifer Paulson; Kristin W Samuelson; Judy K Shigenaga; Carl Grunfeld; Mike W Weiner; Thomas C Neylan
Journal:  Psychoneuroendocrinology       Date:  2014-11-18       Impact factor: 4.905

4.  Hippocampal volume in patients with asthma: Results from the Dallas Heart Study.

Authors:  Scott M Carlson; Julie Kim; David A Khan; Kevin King; Richard T Lucarelli; Roderick McColl; Ronald Peshock; E Sherwood Brown
Journal:  J Asthma       Date:  2016-05-17       Impact factor: 2.515

5.  Neurological outcomes 1 year after COVID-19 diagnosis: A prospective longitudinal cohort study.

Authors:  Verena Rass; Ronny Beer; Alois Josef Schiefecker; Anna Lindner; Mario Kofler; Bogdan Andrei Ianosi; Philipp Mahlknecht; Beatrice Heim; Marina Peball; Federico Carbone; Victoria Limmert; Philipp Kindl; Lauma Putnina; Elena Fava; Sabina Sahanic; Thomas Sonnweber; Wolfgang N Löscher; Julia V Wanschitz; Laura Zamarian; Atbin Djamshidian; Ivan Tancevski; Günter Weiss; Rosa Bellmann-Weiler; Stefan Kiechl; Klaus Seppi; Judith Loeffler-Ragg; Bettina Pfausler; Raimund Helbok
Journal:  Eur J Neurol       Date:  2022-03-23       Impact factor: 6.288

Review 6.  Immediate and long-term consequences of COVID-19 infections for the development of neurological disease.

Authors:  Michael T Heneka; Douglas Golenbock; Eicke Latz; Dave Morgan; Robert Brown
Journal:  Alzheimers Res Ther       Date:  2020-06-04       Impact factor: 6.982

Review 7.  Pathophysiological Clues to How the Emergent SARS-CoV-2 Can Potentially Increase the Susceptibility to Neurodegeneration.

Authors:  Mahsa Dolatshahi; Mohammadmahdi Sabahi; Mohammad Hadi Aarabi
Journal:  Mol Neurobiol       Date:  2021-01-08       Impact factor: 5.590

Review 8.  Cognitive impact of COVID-19: looking beyond the short term.

Authors:  Scott Miners; Patrick G Kehoe; Seth Love
Journal:  Alzheimers Res Ther       Date:  2020-12-30       Impact factor: 6.982

Review 9.  Impact of COVID-19 on the Onset and Progression of Alzheimer's Disease and Related Dementias: A Roadmap for Future Research.

Authors:  Marcia N Gordon; Michael T Heneka; Lydia M Le Page; Christian Limberger; David Morgan; Andrea J Tenner; Niccolò Terrando; Auriel A Willette; Sara A Willette
Journal:  Alzheimers Dement       Date:  2021-12-07       Impact factor: 16.655

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.